Pharmacy World & Science

, Volume 32, Issue 5, pp 594–600 | Cite as

Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacists’ intervention study

  • Hossein KhaliliEmail author
  • Simin Dashti-Khavidaki
  • Azita Hajhossein Talasaz
  • Laleh Mahmoudi
  • Kaveh Eslami
  • Hamed Tabeefar
Research Article


Objective Venous thromboembolism is a major cause of mortality and morbidity in hospitalized patients. To evaluate physicians’ approach to patients’ thrombosis risk assessment and practice of thromboembolism prophylaxis in a teaching hospital, we designed an interventional prospective study. Setting This pre and post interventional study was conducted in the infectious diseases ward of Imam Khomeini referral hospital, Tehran, Iran. Method Patients’ risk factors for thromboembolism during hospitalization course and physicians’ thromboembolism prophylaxis approaches were evaluated in a pre and post clinical pharmacists’ interventional study. Main outcome measure An internal guideline for prescribing anticoagulants as deep vein thrombosis (DVT) prophylaxis was prepared by clinical pharmacists and the appropriateness of anticoagulants’ prescription was evaluated and compared before and after the implementation of consensual guideline. Results In the pre-intervention phase 69.9% of patients had appropriate indication and received thromboembolism prophylaxis and in 31.1% of enrolled patients anticoagulants were prescribed inappropriately. Prescription of anticoagulants was appropriate in 88.4% of patients during the post interventional phase of the study while 11.6% of admitted patients received prophylaxis improperly. A decrease in the number of patients who had the criterion for DVT prophylaxis but anticoagulants were not administered after the implementation of internal guideline was statistically significant (P = 0.001).Conclusion The implementation of clinical pharmacists’ prepared protocol helped to a great extent in the improvement of administrating DVT prophylaxis appropriately in patients.


Clinical pharmacy DVT Infectious diseases 


Conflicts of interest

None declared.


  1. 1.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):381S–453S.CrossRefPubMedGoogle Scholar
  2. 2.
    Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg. 2003;25:1–5.CrossRefPubMedGoogle Scholar
  3. 3.
    White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:14–8.CrossRefGoogle Scholar
  4. 4.
    Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med. 2004;10(5):356–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Tapson VF, Hyers TM, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005;165:1458–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol. 1997;50:609–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen AT, Edmondson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis. 1996;26:65–71.PubMedGoogle Scholar
  8. 8.
    Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis. J R Soc Med. 1989;82:203–5.PubMedGoogle Scholar
  9. 9.
    Cohen AT, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med. 2001;7:332–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.CrossRefPubMedGoogle Scholar
  11. 11.
    Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ. 2006;332:325–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl):338S–400S.CrossRefPubMedGoogle Scholar
  14. 14.
    Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25:101–61.Google Scholar
  15. 15.
    Ageno W, Squizzato A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica. 2002;87:746–50.PubMedGoogle Scholar
  16. 16.
    Ahmad HA, Geissler A, MacLellan DG. Deep venous thrombosis prophylaxis: are guidelines being followed? ANZ J Surg. 2002;72:331–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Bergmann JF, Mouly S. Thromboprophylaxis in medical patients: focus on France. Semin Thromb Hemost. 2002;28(suppl):51–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Goldhaber SZ, Tapson VF. DVT FREE Steering Committee; a prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Dobesh PP, Phillips KW, Haines ST. Improving the use of anticoagulant therapies in acutely ill medical patients. Am J Health Syst Pharm. 2008;65(15 Suppl 7):S5–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Sobieraj DM. Development and implementation of a program to assess medical patients’ need for venous thromboembolism prophylaxis. Am J Health Syst Pharm. 2008;65(18):1755–60.CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia DA, Highfill J, Finnerty K, Varoz E, McConkey S, Hutchinson K. Libby E: a prospective, controlled trial of a pharmacy-driven alert system to increase thromboprophylaxis rates in medical inpatients. Blood Coagul Fibrinolysis. 2009;20:541–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Rahima SA, Panjub A, Paib M, Ginsberg J. Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 2003;111:215–9.CrossRefGoogle Scholar
  23. 23.
    Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library, vol. 2. Oxford: Update Software; 2003;87.Google Scholar
  24. 24.
    Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991;115:591–5.PubMedGoogle Scholar
  25. 25.
    Keane MG, Ingenito EP, Goldhaber SZ. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest. 1994;106:13–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Fernandez BB Jr, Mink AM, Grove MK. Venous thromboembolism prophlylaxis, or lack of [Letter]. Chest. 1995;107:296.CrossRefPubMedGoogle Scholar
  27. 27.
    Bauer JB, Chun DS, Karpinski TA. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm. 2008;65(17):1643–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS a case-control study. J Acquir Immune Defic Syndr. 2008;48(3):310–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165–77.PubMedGoogle Scholar
  31. 31.
    Mant M, Geerts B. Clinical guide—DVT prophylaxis in major orthopedic surgery. The thrombosis interest group of Canada (Sep 2006).Google Scholar
  32. 32.
    Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:71–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Hossein Khalili
    • 1
    Email author
  • Simin Dashti-Khavidaki
    • 1
  • Azita Hajhossein Talasaz
    • 1
  • Laleh Mahmoudi
    • 1
  • Kaveh Eslami
    • 1
  • Hamed Tabeefar
    • 1
  1. 1.Department of Clinical PharmacyFaculty of Pharmacy, Tehran University of Medical SciencesTehranIran

Personalised recommendations